Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from a Phase 3b, Open-Label, Multicenter, Continuation Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A

Eric S. Mullins, MD, Barbara A Konkle, Catherine E. McGuinn, MD, Werner Engl, PhD CStat, Srilatha D. Tangada, PhD

Blood (2018) 132 (Supplement 1): 2483.

https://doi.org/10.1182/blood-2018-99-110190

Published: 2018

Journal Articles

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Jerzy Windyga, Oleksandra Stasyshyn, MD PhD, Werner Engl, PhD CStat, Srilatha D. Tangada, PhD

Blood (2018) 132 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2018-99-111295

Published: 2018

Journal Articles

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Kathelijn Fischer, MD PhD MSc, Pratima Chowdary, FRCPath, MRCPath, MRCP, MD, Peter Collins, MD, Amy Cotterill, PhD, Barbara Konkle, MD, Victor S. Blanchette, FRCP, FRCPC, Steven W. Pipe, MD, Martin Wolfsegger, Cstat (RSS), Werner Engl, PhD Cstat, Jimena V Goldstine, PhD, Leonard A. Valentino, MD FAAP, Gerald Spotts, PhD

Blood (2016) 128 (22): 2576.

https://doi.org/10.1182/blood.V128.22.2576.2576

Published: 2016

Journal Articles

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Eric S. Mullins, MD, Christine M. Knoll, MD, Amy L. Dunn, MD, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 1409.

https://doi.org/10.1182/blood.V128.22.1409.1409

Published: 2016

Journal Articles

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Amy L. Dunn, MD, Alexis A. Thompson, MD MPH, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 3778.

https://doi.org/10.1182/blood.V128.22.3778.3778

Published: 2016

Journal Articles

Target Joint Status in Patients with Hemophilia a during 18 Consecutive Months of Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 2592.

https://doi.org/10.1182/blood.V128.22.2592.2592

Published: 2016

Journal Articles

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

Frank Michael Horling, PhD, Peter Allacher, PhD, Herwig Koppensteiner, PhD, Werner Engl, PhD Cstat, Fritz Scheiflinger, PhD, Brigitt E. Abbuehl, MD, Birgit M Reipert, PhD

Blood (2016) 128 (22): 2594.

https://doi.org/10.1182/blood.V128.22.2594.2594

Published: 2016

Journal Articles

An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a

Werner Engl, PhD Cstat, Lisa Patrone, PhD, Dyck-Jones Jacqueline, PhD, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 3801.

https://doi.org/10.1182/blood.V128.22.3801.3801

Published: 2016

Journal Articles

Detection of Non Inhibitory Binding Antibodies to Von Willebrand Factor Affecting the Clearance of VWF:Ag in Von Willebrand Disease

Blood (2011) 118 (21): 2275.

https://doi.org/10.1182/blood.V118.21.2275.2275

Published: 2011

Journal Articles

Efficacy and Safety of a New Intravenous Immunoglobulin in Adult Subjects with Chronic Idiopathic Thrombocytopenic Purpura.

Heinz Leibl, PhD, Gyula Varga, MD, Zuzana Volkova, MD, Zoltan Gasztonyi, MD, Antonin Hlusi, MD, Jiri Mayer, MD, Krzysztof Chojnowski, MD, Hans-Heinrich Wolf, MD, Marlies Sharkhawy, MA, Borislava G. Pavlova, PhD, Karl Birthistle, MD, Werner Engl, PhD, Simone Walter, MS, Hartmut J. Ehrlich, MD

Blood (2005) 106 (11): 3984.

https://doi.org/10.1182/blood.V106.11.3984.3984

Published: 2005

NARROW

Efficacy and Safety Results from a Phase 3b, Open-Label, Multicenter, Continuation Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A

Evaluation of the Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma (BAX326) in Previously Treated and Naïve Patients with Severe or Moderately Severe Hemophilia B: A Continuation Study

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Target Joint Status in Patients with Hemophilia a during 18 Consecutive Months of Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Immunogenicity of BAX 855 in Previously Treated Patients with Congenital Severe Hemophilia Α

An Evaluation of Safety with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855) in the Treatment of 243 Patients with Hemophilia a

Detection of Non Inhibitory Binding Antibodies to Von Willebrand Factor Affecting the Clearance of VWF:Ag in Von Willebrand Disease

Efficacy and Safety of a New Intravenous Immunoglobulin in Adult Subjects with Chronic Idiopathic Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only